Targets › COBL
1 program from 1 company in 1 trial: 1 Phase 4; Ophthalmology; next expected readout May 2027.
Plays an important role in the reorganization of the actin cytoskeleton. Regulates neuron morphogenesis and increases branching of axons and dendrites. (UniProt, O75128)
Open in Phaseline: the race on COBL, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| First Affiliated Hospital of Chongqing Medical University | Mecobalamin Vitamin B12 derivative with neuroprotective effects | COBL | Phase 4 | Retinal Vein Occlusion (RVO) | May 2027 |
Retinal Vein Occlusion (RVO) (1)
small molecule (1)
First Affiliated Hospital of Chongqing Medical University (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.